In this class of myeloid malignancies, SETBP1 mutations were observed in about 4-7% of patients when the analysis was performed with conventional sequencing methods [84, 89–91]; instead, when deep sequencing was employed, the mutation rate rose to 15%-19% [58, 92]. Here, SETBP1 is linked to myeloid neoplasm.